Formulations of a transdermal patch for pain management

Abstract

Various formulations (to be used in the form of a single-segment or multi-segment transdermal patch) of bioactive compounds for pain management are described/disclosed. The multi-segmented transdermal patch can include one or more compatible bioactive compounds in each segment. Furthermore, formulations may include silk fibroin and/or microemulsion/nanoemulsion of bioactive compounds and/or microencapsulation/nanoencapsulation of bioactive compounds.

Claims

1. A transdermal patch for pain management, comprising: pharmaceutical formulation of ##STR00003## (a) cannabidiol (CBD) or cannabidiol (CBD) pro-drug; (b) silk fibroin; (c) Boswellia serrata extract; and (d) a bioactive compound astaxanthin.

2. The transdermal patch according to claim 1, is a single segment transdermal patch.

3. The transdermal patch according to claim 1, comprises: cannabidiol (CBD) or cannabidiol (CBD) pro-drug in microemulsion.

4. The transdermal patch according to claim 1, further comprises: a permeation enhancement compound.

5. A transdermal patch for pain management, comprising: pharmaceutical formulation of ##STR00004## (a) cannabidiol (CBD) or cannabidiol (CBD) pro-drug; ##STR00005## (b) cannabichromene (CBC) or cannabichromene (CBC) pro-drug; (c) silk fibroin; (d) Boswellia serrata extract; and (e) a bioactive compound astaxanthin.

6. The transdermal patch according to claim 5, is a single segment transdermal patch.

7. The transdermal patch according to claim 5, comprises: cannabidiol (CBD) or cannabidiol (CBD) pro-drug in microemulsion.

8. The transdermal patch according to claim 5, further comprises: a permeation enhancement compound.

9. A transdermal patch for pain management, comprising: pharmaceutical formulation of ##STR00006## (a) cannabidiol or cannabidiol pro-drug; ##STR00007## (b) cannabichromene or cannabichromene pro-drug; (c) Boswellia serrata extract or capsaicin; (d) silk fibroin; and (e) a bioactive compound astaxanthin.

10. A transdermal patch for pain management, comprising: pharmaceutical formulation of (a) Boswellia serrata extract; (b) capsaicin; (c) silk fibroin, and (d) a bioactive compound astaxanthin.

11. The transdermal patch according to claim 10, is a single segment transdermal patch.

12. The transdermal patch according to claim 10, further comprises: a permeation enhancement compound.

Description

PREFERRED EMBODIMENTS OF SPECIFICATIONS

(1) In the above disclosed specifications / has been used to indicate an or.

(2) Any example in the above disclosed specifications is by way of an example only and not by way of any limitation. The best mode requirement requires an inventor to disclose the best mode contemplated by him/her, as of the time he/she executes the application, of carrying out the invention. . . . [T]he existence of a best mode is a purely subjective matter depending upon what the inventor actually believed at the time the application was filed. See Bayer AG v. Schein Pharmaceuticals, Inc. The best mode requirement still exists under the America Invents Act (AIA). At the time of the invention, the inventor described preferred best mode embodiments of the present invention. The sole purpose of the best mode requirement is to restrain the inventor from applying for a patent, while at the same time concealing from the public preferred embodiments of their inventions, which they have in fact conceived. The best mode inquiry focuses on the inventor's state of mind at the time he/she filed the patent application, raising a subjective factual question. The specificity of disclosure required to comply with the best mode requirement must be determined by the knowledge of facts within the possession of the inventor at the time of filing the patent application. See Glaxo, Inc. v. Novopharm LTD., 52 F.3d 1043, 1050 (Fed. Cir. 1995).

(3) The above disclosed specifications are the preferred best mode embodiments of the present invention. However, they are not intended to be limited only to the preferred best mode embodiments of the present invention. Numerous variations and/or modifications are possible within the scope of the present invention. Accordingly, the disclosed preferred best mode embodiments are to be construed as illustrative only. Those who are skilled in the art can make various variations and/or modifications without departing from the scope and spirit of this invention. The inventor of the present invention is not required to describe each and every conceivable and possible future embodiment in the preferred best mode embodiments of the present invention. See SRI Int'l v. Matsushita Elec. Corp. of America, 775F.2d 1107, 1121, 227 U.S.P.Q. (BNA) 577, 585 (Fed. Cir. 1985) (enbanc).